Zalicus Inc Com (NASDAQ:ZLCS)

CAPS Rating: 4 out of 5

A biopharmaceutical company pioneering the new field of synergistic combination pharmaceuticals, with a portfolio of product candidates in phase 2 clinical development.

Recs

0
Player Avatar ayuddha (< 20) Submitted: 7/15/2012 5:18:50 PM : Outperform Start Price: $1.15 ZLCS Score: -11.79

It was picked by www.hechtsoft.de Trade Alerts.

Featured Broker Partners


Advertisement